BioCentury | Oct 11, 2012
Distillery Therapeutics

Indication: Neurology

...mouse model of SBMA, reduction of Cgrp expression, using the serotonin (5-HT1D) receptor agonist Amerge naratriptan...
...control. Next steps include Phase II trials of Amerge in the indication. GlaxoSmithKline plc markets Amerge...
BioCentury | Oct 11, 2012
Targets & Mechanisms

Repurposing naratriptan

...Japanese researchers have shown in mice that GlaxoSmithKline plc 's marketed migraine drug Amerge naratriptan could...
...migraine therapeutics also could help treat SBMA. In human neuroblastoma cells expressing pathogenic AR , naratriptan...
...Institute of Technology , said it is worth testing naratriptan in SBMA but noted that "naratriptan's...
BioCentury | Jul 7, 2008
Product Development

Cleaner than triptans

...in U.S. sales and €22.1 million ($30.3 million) in European sales. Revenue data for Amerge naratriptan...
BioCentury | Oct 29, 2007
Product Development

Tezampanel vs. triptans

...vs. placebo) 6 mg Imitrex SC 15 86% (p<0.01 vs. placebo) Placebo 16 25% Amerge naratriptan...
BioCentury | Oct 8, 2007
Regulation

Significant isn't meaningful

...There are six triptans on the market for the acute treatment of migraine: Frova; Amerge naratriptan...
BioCentury | Oct 10, 2005
Company News

Allergan, GlaxoSmithKline sales and marketing update

...received U.S. co-promotion rights to two GSK migraine drugs: Imitrex sumatriptan STATdose System and Amerge naratriptan...
BioCentury | Feb 11, 2002
Finance

CNS franchises

...and Sarafem ($2B); Zyprexa ($3.1B) NA $10,857 GlaxoSmithKline (A) Seroxat/Paxil ($2318M); Wellbutrin ($676M); Imigran/Imitrex ($1054M); Naramig/Amerge...
BioCentury | Dec 3, 2001
Clinical News

Triptans: Marketed

...eletriptan and almotriptan gave patients the greatest relief with the greatest consistency compared to sumatriptan, naratriptan...
...or better efficacy and consistency compared to sumatriptan with fewer adverse events, while those given naratriptan...
BioCentury | Nov 1, 1999
Company News

Glaxo Wellcome, Schwarz Pharma sales and marketing update

...Schwarz will exclusively co-promote in Germany Glaxo's Naramig naratriptan, a 5HT1D agonist to treat migraines. Glaxo...
BioCentury | May 18, 1998
Strategy

Vanguard's headache

...the market for nearly a decade. Second-generation 5HT1D agonists on the market include Glaxo's Naramig naratriptan...
Items per page:
1 - 10 of 10